JPMorgan lowered the firm’s price target on Regeneron (REGN ... particularly as we near a number of pipeline readouts, the analyst tells investors in a research note. Published first on TheFly ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ ...

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by JP Morgan on June 9, 2025. The analyst firm set a price target for $800.00 expecting REGN to rise to within 12 ...

Deciphering Analyst Ratings: An In-Depth Analysis A clear picture of Regeneron Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions.

JPMorgan Chase stock slipped after an analyst recommended that clients sell because it appears too expensive after a run-up to record highs. David George, an analyst at Baird, wrote in a report th ...

Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments ...

In this article, we will take a look into JPMorgan Chase & Co's (NYSE:JPM) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash ...

This comprehensive analysis examines Regeneron’s current position, future prospects, and the factors that could shape its trajectory in the coming years. Regeneron focuses on developing and ...

On Tuesday, Morgan Stanley (NYSE: MS) adjusted its outlook on Regeneron (NASDAQ: REGN) Pharmaceuticals stock, reducing the price target from $1,185.00 to $1,150.00.Despite the decrease, the firm ...